510(k) device
Insulin Pump
Abbott Diabetes Care, Inc. · Pump, Infusion, Insulin (LZG, Class II) · First FDA decision Dec 23, 2005, newest Dec 23, 2005Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1,137
Naming "Insulin"
MAUDE reports
2,491,421
Brand "Insulin", since 2015
PubMed studies
465,237
Mentioning "Insulin"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Insulin Pump
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- INSULIN PUMP510(k)
K051041 · Decided Dec 23, 2005 · 242 days after receipt
Device type: Pump, Infusion, Insulin (LZG) · Hospital Medicine & Nursing
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Insulin Infusion PumpNational analysisReview closedCAG-00041NUpdated Sep 14, 2026
- Insulin Pump: C-Peptide Levels as a Criterion for UseNational analysisReview closedCAG-00092NUpdated Nov 20, 2026
- Outpatient Intravenous Insulin Treatment (Therapy)National analysisReview closedCAG-00410NUpdated Sep 18, 2026
- Insulin Pump: C-Peptide Levels as a Criterion for UseNational analysisReview closedCAG-00092RUpdated Sep 18, 2026
- Outpatient Intravenous Insulin TreatmentNational determinationOn the books40.7Updated Aug 16, 2023
- Insulin SyringeNational determinationOn the books40.4Updated Jun 11, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Insulin", any status and sponsor, newest update first.
- Genetic Studies of Insulin and DiabetesRecruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00001987 · 1,200 participants (planned) · Start Feb 1, 1976
Device: HR-pQCT scan · For: Diabetes Mellitus; Severe Insulin Resistance
Sites: Bethesda, Maryland
1,136 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Insulin", and for the whole product code for context.
This brand
2,491,421 reports: 2,143,449 malfunction, 344,340 injury, 3,384 death
Whole product code LZG
385,399 reports: 329,529 malfunction, 55,119 injury, 355 death
Newest reports for this brand
- Omnipod 5 Automated Insulin Delivery SystemMalfunction
3014585508-2026-79826 · Received Oct 30, 2026 · Event dated Oct 14, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Obstruction of Flow; Insufficient Device Problem Information
Patient problem as coded: Hemorrhage/Blood Loss/Bleeding; Hyperglycemia
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Insulin"[tiab]. The summary above synthesizes these.
- Insulin signaling and its application.
Le TKC, Dao XD, Nguyen DV, et al. · Front Endocrinol (Lausanne) · 2023Review
- Insulin dysregulation.
Frank N, Tadros EM · Equine Vet J · 2014Review
- Insulin aspart.
Simpson KL, Spencer CM · Drugs · 1999Review
- Insulin therapy.
Lechleitner M, Hoppichler F · Wien Med Wochenschr · 2011Comparative Study, Review
- New classification and diagnostic criteria for insulin resistance syndrome.
Ogawa W, Araki E, Ishigaki Y, et al. · Endocr J · 2022
- Insulin and the blood-brain barrier.
Rhea EM, Banks WA · Vitam Horm · 2024Review, Research Support, N.I.H., Extramural
- Recent Advances in Insulin Therapy.
Wilson LM, Castle JR · Diabetes Technol Ther · 2020Research Support, N.I.H., Extramural, Review
- Insulin analogues.
Marks J · Postgrad Med · 2002Research Support, Non-U.S. Gov't
- Personalized phosphoproteomics of skeletal muscle insulin resistance and exercise links MINDY1 to insulin action.
Needham EJ, Hingst JR, Onslev JD, et al. · Cell Metab · 2024
- The coming of weekly insulin.
Rendell M · Expert Opin Pharmacother · 2026Editorial
- [Insulin resistance].
Waldhäusl W · Acta Med Austriaca · 1992English Abstract, Review
Other devices of this type
Also filed under product code LZG.
- Omnipod® Insulin Management System, Omnipod DASH® Insulin Management SystemInsulet Corporation · 510(k) 2021
- t:slim Insulin Delivery System, t:flex Insulin Delivery SystemTandem Diabetes Care, Inc. · 510(k) 2016
- Medtronic Minimed Paradigm Insulin PumpsMedtronic Minimed · 510(k) 2012
- Pivot Insulin Delivery SystemModular Medical, Inc. · 510(k) 2026
- Extended ReservoirMedtronic Minimed · 510(k) 2024
- Amigo Insulin PumpNipro Diabetes Systems, Inc. · 510(k) 2007
- Modular Medical MODD1 Insulin Delivery SystemModular Medical, Inc. · 510(k) 2024
- Omnipod GO Insulin Delivery DeviceInsulet Corporation · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.